Stocksigma LogoStocksigma Logo

Balaxi Pharmaceuticals Receives WHO-GMP Certification and Posts Q2 Financial Results

Balaxi Pharmaceuticals secured WHO-GMP certification from CDSCO for its Jadcherla formulation facility, scaling up commercial production for Angola and

Balaxi Pharmaceuticals Receives WHO-GMP Certification and Posts Q2 Financial Results

Balaxi Pharmaceuticals Ltd · Outcome · 12 Nov 2026, 7:37 pm

Balaxi Pharmaceuticals Receives WHO-GMP Certification and Posts Q2 Financial Results Balaxi Pharmaceuticals secured WHO-GMP certification from CDSCO for its Jadcherla formulation facility, scaling up commercial production for Angola and Dominican Republic markets with 22 products manufactured and approvals for 34 products. For the quarter ended 30th Sep'26, consolidated revenue from operations rose 44.85% YoY to Rs 8,137.23 lakhs, while consolidated net profit surged to Rs 115.02 lakhs against Rs 20.90 lakhs in the previous year quarter. Additionally, Pranav Maheshwari was redesignated as President – Business and Corporate Strategy effective 12th Nov'26.

Original exchange filing (PDF)

More announcements from Balaxi Pharmaceuticals Ltd

All Balaxi Pharmaceuticals Ltd announcements